Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
Collection content
305 result(s) found, displaying 41 to 50
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
News articlesThe TGA is aware of concerns about decreased effectiveness of monoclonal antibodies against the COVID-19 caused by emerging SAR-COV-2 variants. At this stage, the regulatory status of the products remain unchanged in Australia.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesOn 17 February, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine. This is the second bivalent vaccine targeting the Omicron BA.4-5 subvariants that has been provisionally approved by the TGA
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has confirmed the performance of COVID-19 rapid antigen tests available on the Australian market with COVID-19 variants.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThis is the first vaccine provisionally approved by the TGA that is designed to specifically target the Omicron variants BA.4/BA.5 and follows provisional approval of the Pfizer BA.1 Omicron/original bivalent vaccine.
-
Media releasesThe TGA has commenced evaluation of an application from Moderna Australia Pty Ltd to transition its COVID-19 vaccine, SPIKEVAX, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.